←Palliative Care
Study register · detail Offene unkontrollierte Pilotstudie · Palliative Care · 1983

Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.

Gerhartz et al. ·Journal of Molecular Medicine
Clear benefit GRADE Moderate 6 citations
Samplen = 20 Pat.
EndpointAntiemetic response
Blindingn.a.
DesignOffene unkontrollierte Pilotstudie
Cannabinoidthc
Key finding

Levonantradol produced a substantial antiemetic effect in 15 of 20 refractory patients.

Summary

n=20 cancer patients with treatment-refractory chemotherapy-induced nausea/vomiting in a palliative context; levonantradol (THC analogue): 15/20 (75%) marked symptom relief, 10/20 preferred continuation — suggestion of benefit in conventionally exhausted patients.

P
PopulationCancer patients with chemotherapy-induced nausea/vomiting, refractory to conventional antiemesis, n=20
I
InterventionLevonantradol (synthetic tetrahydrocannabinoid), dosage/administration not further specified
O
Outcome15 of 20 patients (75%) showed substantial relief; 10 of these preferred the medication for further chemotherapy cycles
Confidence in the evidence
Moderate

The third of four GRADE levels, the effect estimate is probably reliable.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Gerhartz HH, Binsack T, Hiller E.
DOI 10.1007/bf01487619↗
Design: Offene unkontrollierte Pilotstudie
Share
Abstract
Twenty patients with cancer previously unresponsive to antiemetic treatment of chemotherapy-induced nausea and vomiting were treated with the new tetrahydrocannabinoid Levonantradol. 15 patients experienced substantial relief and 10 of them preferred the drug for further courses. These observations suggest that Levonantradol can be beneficial to patients refractory to conventional antiemetic therapy.
Indication
Further studies on Palliative Care
All studies →
S Hauser et al. · 2023 · The Cochrane database of systematic reviews
53 citations
Cannabis-based medicines and medical cannabis for adults with cancer pain.
No benefit demonstrated Meta-Analyse

Cochrane SR zu Cannabis-basierten Medikamenten bei Tumorschmerz (Erwachsene). Evaluiert Nutzen und Schäden vs. Placebo oder etablierte Analgetika; primäre Outcomes: ≤mild pain, PGIC much/very much improved, Withdrawals due to AE. Suche bis 26.01.2023, Einschlusskriterien: doppelblinde RCTs, ≥10 Teilnehmende pro Arm.

10.1002/14651858.cd014915.pub2 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für chronischen Schmerz (inkl. Krebs-assoziierter Schmerz) und MS-Spastik, schwache Evidenz für Chemotherapie-induzierte Übelkeit/Erbrechen, Appetitanregung bei HIV/AIDS und palliative Symptomkontrolle.

10.1001/jama.2015.6358 View study →
A Doppen et al. · 2022 · Journal of pain and symptom management
44 citations
Cannabis in Palliative Care: A Systematic Review of Current Evidence.
Mixed Systematic Review

Systematische Review zu Cannabis in der Palliativmedizin; k=52 Studien (20 RCTs, 32 nicht-randomisierte), n=4.786 Teilnehmende (Krebs n=4.491, Demenz n=43, AIDS n=235, Spastik n=16). Positive Behandlungseffekte (p<0.05) für einige Cannabis-Produkte bei Schmerz, Übelkeit/Erbrechen, Appetit, Schlaf, Fatigue bei Krebs-Patienten; Appetit/Agitation bei Demenz; Appetit/Übelkeit bei AIDS. Evidenzqualität durchgehend 'very low' oder 'low'. Meta-Analyse nicht durchführbar aufgrund Heterogenität der Produkte und Outcomes.

10.1016/j.jpainsymman.2022.06.002 View study →

The impediment to action advances action. — Marcus Aurelius